The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males.

Susanna Croci$^{1,2}$, Mary Anna Venneri$^3$, Stefania Mantovani$^4$, Chiara Fallerini$^{1,2}$, Elisa Benetti$^2$, Nicola Picchiotti$^{5,6}$, Federica Campolo$^3$, Francesco Imperatore$^{7,8}$, Maria Palmieri$^{1,2}$, Sergio Daga$^{1,2}$, Chiara Gabbi$^9$, Francesca Montagnani$^{2,10}$, Giada Beligni$^{1,2}$, Ticiane D.J. Farias$^{11}$, Miriam Lucia Carriero$^{1,2}$, Laura Di Sarno$^{1,2}$, Diana Alaverdian$^{1,2}$, Sigrid Aslaksen$^{12}$, Maria Vittoria Cubellis$^{13}$, Ottavia Spiga$^{14}$, Margherita Baldassarri$^{1,2}$, Francesca Fava$^{1,2}$, Paul J. Norman$^{11}$, Elisa Frullanti$^{1,2}$, Andrea M. Isidori$^3$, Antonio Amoroso$^{15,16}$, Francesca Mari$^{1,2,17}$, Simone Furini$^2$, Mario U Mondelli$^{18,19}$, GEN-COVID multicenter study, Mario Chiariello$^{7,8}$*, Alessandra Renieri$^{1,2,17,*}$, Ilaria Meloni$^{1,2}$.

1) Medical Genetics, University of Siena, Italy
2) Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy
3) Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
4) Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
5) University of Siena, DIISM-SAILAB, Siena, Italy
6) Department of Mathematics, University of Pavia, Pavia, Italy
7) Istituto per lo Studio, la Prevenzione e la Rete Oncologica (ISPRO), Via Fiorentina, 1 53100 Siena, Italy
8) Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Via Fiorentina 1, 53100 Siena, Italy
9) Independent Medical Scientist, Milan, Italy
10) Department of Medical Sciences, Infectious and Tropical Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
11) Division of Biomedical Informatics and Personalized Medicine, and Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
12) Department of Clinical Science, University of Bergen and K.G. Jebsen Center for Autoimmune Diseases, University of Bergen, Bergen, Norway.
13) Department of Biology, Università degli Studi di Napoli "Federico II", Napoli, Italy
14) Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena 53100, Italy
15) Department of Medical Sciences, University of Turin, Italy
16) Immunogenetics and Transplant Biology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Italy.
17) Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy
18) Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
19) Department of Internal Medicine and Therapeutics, University of Pavia, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
* Corresponding author:
Professor Alessandra Renieri
Medical Genetics Unit
University of Siena
Policlinico Le Scotte
Viale Bracci, 2, 53100 Siena, Italy
Phone: +39 0577 233303
Fax: +39 0577 233325
E.mail: alessandra.renieri@unisi.it

Dr. Mario Chiariello
Core Research Laboratory (CRL)
Institute for the Study, Prevention and Oncology Network (ISPRO)
Via Fiorentina 1, 53100 Siena
Phone: +39 0577 231274
E.mail: m.chiariello@ispro.toscana.it
ABSTRACT

The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired autophagy and reduced TNFα production was demonstrated in HEK293 cells transfected with TLR3-L412F plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (P=0.038). An increased frequency of autoimmune disorders as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways.
INTRODUCTION

In December 2019, a new virus was isolated in Wuhan, China, which was called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is an enveloped positive-sense RNA virus that caused a new pandemic which WHO named COVID-19 (CoronaVirus Disease-2019).

To date, many characteristics of SARS-CoV-2 are still unclear and, although its ability to be transmitted from one person to another has been ascertained, uncertainties remain about the exact modes of transmission and pathogenicity. In addition, a high variability of symptoms in infected patients and between different populations has been reported; one of the possible explanations of such variability is the genetic background of the host that may affect immune responses to the virus. Among host genetic factors that might impact on symptoms severity there are genes involved in virus entry and mediators of innate immunity [1,2]. Toll-Like Receptors (TLRs) are a class of proteins that play a key role in host innate immunity, causing the production of pro-inflammatory cytokines (TNF-α, IL-1, and IL-6) and type I and II Interferons (IFN), that are responsible for innate antiviral responses. Among TLR genes, TLR3 is an interferon-inducing dsRNA sensor, whose activation is involved in protection against different RNA viruses [2-4]. Upon viral infection, TLR3 signalling leads to the activation of two factors, NF-kB and Interferon (IFN)-Regulatory Factor 3 (IRF3), that play an essential role in the immune response. This results in the production of various cytokines, including tumor necrosis factor-α (TNF-α), activating immune responses. However, increased inflammatory responses can make the patient more susceptible to pneumonia and autoimmune diseases. Accordingly, a protective effect against fatal pneumonia has been reported in the absence of TLR3 [5-7]. Among TLR3 variants, the functional L412F polymorphism (rs3775291; c.1234C>T) is known to decrease TLR3 expression on the cell surface [8]. This polymorphism
also leads to poor recognition of SARS-CoV-2 dsRNA compared to its wild type counterpart [9] and has been recently associated with SARS-CoV-2 susceptibility and mortality [10]. There is evidence that TLR3, as other TLRs, acts through autophagy in determining susceptibility to infections [11]. The autophagic pathway is essential during infection and for molecular processes as cell maintenance and homeostasis [11-14]. Indeed, autophagy is one of the major cell defence mechanisms against pathogens [15]. A role for autophagy is reported in different studies on other Coronaviruses such as the mouse hepatitis virus (MHV) and the transmissible gastroenteritis virus (TGEV) [16,17]. A role in SARS-CoV-2 infection has also been described [18-20]. In particular, SARS-CoV-2 can inhibit autophagy resulting in accumulation of autophagosomes and inhibition of viral clearance that, together with immune dysfunction and the activation of numerous inflammatory cytokines, leads to a more severe form of COVID-19 [21-23].

To shed light on the mechanisms underlying the diverse susceptibility to COVID-19, we performed a nested-control study within our GEN-COVID cohort, confirming the role of L412F polymorphism in TLR3 gene in susceptibility to SARS-CoV-2 and further defining the potential mechanisms by which this effect is exerted.
RESULTS AND DISCUSSION

Comparing the extreme phenotypes of SARS-CoV-2 infection, severe COVID-19 patients (cases) versus SARS-CoV-2 PCR-positive oligo-asymptomatic subjects (controls), and using LASSO Logistic regression on common bi-allelic polymorphisms from whole-exome sequencing, we identified the L412F polymorphism (rs3775291; c.1234C>T) in TLR3 as a severity marker (Fig. 1A). The grid search curve of the cross-validation score (Fig.1B) shows a maximum of the regularization parameter in 10. With this calibration setting, the 10-fold cross-validation provides good performances in terms of accuracy (73%), precision (74%), sensitivity (73%), and specificity (73%) as shown in Fig.1C. The confusion matrix is reported in Fig.1D, whereas the Receiver Operating Characteristic (ROC) curve (Fig.1E) provides an Area Under the Curve (AUC) score of 80%.

The L412F polymorphism has an overall allele frequency of about 20%, ranging from 30% in European to 0.88% in African (mainly sub Saharan) populations [8]. It is intriguing that a COVID-19-free population such as sub Saharan has a very low frequency (0.88%) of this polymorphism and that Asian (26.97%) and European (30.01%) have a much higher frequency. The variant protein with phenylalanine is under-represented on the cell surface, it is not efficiently secreted into the culture medium when expressed as the soluble ectodomain, and it has reduced capability to activate the expression of TLR3-dependent reporter constructs [8]. In order to confirm the role of the polymorphism, we compared individuals showing severe COVID-19 (cases) and those with no sign of the disease (controls). We subdivided patients in two categories, those having the polymorphism in heterozygous or homozygous state and those homozygous for the wild type allele. We found that the prevalence of L412F polymorphism is significantly higher in cases compared to controls (p-value $2.8\times10^{-2}$) (Table 1a). The global allele frequency of L412F in our cohort (cases and controls) is 29.38%, like to the allele frequency of 29.79% reported in the European (non-Finnish) population in the gnomAD
database (https://gnomad.broadinstitute.org/). The identified frequencies were in Hardy-Weinberg equilibrium.

Sex-related differences of TLRs activation following stimulation by viral nucleic acid may be involved in the sex-related variability in response to viral infections [24]. Several rare TLR3 loss of function mutations are known linked both to influenza and SARS-CoV-2 virus as well as hyperfunctioning mutations [25, 26]. In agreement with these data, when we stratified by gender, the statistically significant difference increased in the sub-cohort of males giving an OR of 1.94 (95% CI, 1.23 to 3.06; p=3.8x10^{-3}), while it was lost in the sub-cohort of females (p-value 5.8x10^{-1}) (Table 1).

We then investigated the prevalence of patients carrying L412F in heterozygous or homozygous states in all 4 categories of COVID-19 clinical severity, considering only male subjects regardless of age (n=665). We found that the prevalence of carriers directly increased with the severity of COVID-19, from a clinical condition not requiring hospitalization to intratracheal intubation (Fig. 1F).

The L412F substitution in TLR3 falls in the ectodomain, in the 14 Leucine-Rich Repeats (LRR) domain, a motif of 22 amino acids in length that folds into a horseshoe shape [27]. Proteins containing LRRs are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response [slit: an extracellular protein necessary for development of midline glia and commissural axon pathways contains both EGF and LRR domains [28]. The L412F substitution is expected to have a limited structural impact with minimal rearrangement of near hydrophobic amino acids like tryptophan 386 (Fig. 2). However, the absence of one of the leucines probably determines a different rearrangement of the motif and consequently of the near glycosylation site ASN414, having an impact on protein-protein interaction and in signal transduction process [29].
Germline knockout of TLR3 inhibits autophagy and upregulation of TLR3 promotes damage after myocardial infarction mainly because of autophagy rather than inflammatory activation [30]. Interestingly, we could notice a statistically significant (p=3.8x10^{-2}) reduced survival at 28 days in TLR3_L412F COVID-19 patients treated with hydroxychloroquine (HCQ) (Fig.3A). As this drug is a well-established inhibitor of autophagy, we reasoned that alterations of this important biological process might have a role in the increased severity of the clinical phenotypes of SARS-CoV-2 infection in patients with the TLR3_L412F polymorphism. Notably, beside being entirely ineffective at changing the clinical evolution of COVID-19, which led to retraction of the paper reporting the clinical trial [31], HCQ may have been responsible for reportedly increased fatality rates among patients treated with this drug [32,33]. Poly(I:C) stimulation of the TLR3 receptor has already been shown to stimulate autophagy [30]. Therefore, we decided to compare the efficacy of transfected WT and L412F-mutated receptors in inducing autophagy upon poly(I:C) treatment. To monitor autophagy, we used indirect immunofluorescence microscopy to score the formation of punctate intracellular vacuoles stained for LC3B. Moreover, to better appreciate autophagosomal formation, we also used bafilomycin A1 (Baf A1), an inhibitor of lysosomal acidification, to prevent lysosomal degradation of autophagosome-associated LC3B [34]. Baf A1 allows, in fact, the detection of each autophagosome formed in the time-lapse between addition of the drug to cells and harvesting [34]. Importantly, to avoid potentially confounding effects of the endogenous TLR3 receptor in transfected cells, we used TLR3 knock-out HEK cells. In these cells, when transfected with TLR3_WT, we observed a progressively increasing number of autophagosomes (AP) when stimulating with poly(I:C) for different time points in the presence of BAF A1 (compared to BAF A1 alone) (Fig. 3B-C), indicating a stimulation of the synthesis of these vesicles and a positive autophagic flux. Conversely, in HEK cells transfected with TLR3_L412F, the number of AP was reduced by poly(I:C) stimulation in the presence of BAF
A1 (Fig. 3B-C), demonstrating a block in AP synthesis and a reduced autophagic flux. Interestingly, in the absence of BAF A1, AP numbers did not increase upon poly(I:C) stimulation, suggesting that, in HEK cells, fast degradation of AP may compensate for a small increase in the synthesis. Indeed, also rapamycin (RAP), a strong stimulus for autophagy [35], induced only a small increase of AP in the absence of BAF A1 in these cells upon transfection of both TLR3_WT and TLR3_L412F, supporting slow rates of AP synthesis in these cells upon stimulation with different stimuli.

During SARS-CoV-2 infection, adipocytes produce pro-inflammatory cytokines like TNF-α, IL-6 and IL-1β which recruit immune cells to the site of infection [36]. Autophagy is stimulated and regulated by these pro-inflammatory cytokines [36]. TNF-α is a potent immunomodulator and proinflammatory cytokine that has been implicated in the pathogenesis of autoimmune and infectious diseases. It is produced by activated monocytes and macrophages, as well as by many other cell types, including lymphocytes, as a transmembrane protein. Through cell modulation, TNF-α can activate both cell death and survival mechanisms. TNF-α induces autophagy through a feedback mechanism, causing further recruitment and activation of lymphocytes and contributing to the excess inflammation typical of SARS-CoV-2 infection [37]. As chloroquine, a powerful inhibitor of autophagy, inhibits production of different cytokines, among which TNF-α [38], we next decided to test if the inhibitory effect of the L412F mutation on autophagy was also able to mimic the effect of the pharmacological inhibitor of this process in HEK cells. Indeed, while poly(I:C) readily stimulated TNFα expression in HEK cells transfected with the TLR3_WT receptor, this effect was completely abolished in TLR3_L412F transfected cells (Fig. 3D).

In order to validate data obtained on transfected HEK cells, we next isolated and cultured skin fibroblasts from healthy donors with different genotypes relative to the TLR3 locus: wild-type (WT/WT) and L412F (L412F/L412F) homozygous and WT/L412F heterozygous. In these
primary fibroblasts, immunofluorescence analysis revealed that the number of LC3B-positive vesicles increased upon poly(I:C) stimulation both in the absence and in the presence of BAF A1 (Fig. 3E-F), showing an overall positive autophagic flux in these cells, while resulting significantly reduced in L412F/L412F fibroblasts (Fig. 3G-H). As a control, rapamycin stimulation of both WT/WT and L412F/L412F resulted in a positive autophagic flux (Fig. 3E-F and G-H) confirming that the mutation specifically affected TLR3-dependent autophagy and not the general autophagic process.

Overall, our results therefore suggest that the outcome of clinical trials with HCQ should be reinterpreted in the light of TLR-L412F polymorphism status. Negative effects of the drug in L412F bearing subjects, may have masked a possible positive outcome in L412F-free subjects.

TLR3 variant L412F has been associated with a wide range of autoimmune diseases including Addison’s disease and hypothyroidism [39]. TLR3 rare variants resulting in partial loss of function and occurring together with the common variant L412F, or with another rare variant, have been identified in Addison’s disease [40]. Persistent viral infections in a background of defective innate immunity lead to overexpression of HLA haplotypes prone to present autoantigen. Defects of autophagy have been observed in many infectious and autoimmune diseases. Alteration of autophagic processes causes the onset of autoimmunity due to increased survival and reduced apoptosis of self-reactive lymphocytes [41-43]. HLA has been shown to be implicated in disease severity and clinical outcome of patients with COVID-19 [44]. Accordingly, an increased frequency of autoimmune disorders as co-morbidity was found in our cohort in L412F COVID-19 patients with specific HLA class II haplotypes prone to autoantigen presentation. In particular, we analysed a DR3-DQ2 haplotype which predisposes to different types of autoimmune diseases [45,46]. The frequency of autoimmune disorders is indeed significantly increased in male patients with HLA DR3/DQ2 haplotype and L412F, especially diabetes (25%) (Table 2a and b). These results suggest that the combination
of L412F in TLR3 and a specific class II HLA haplotype puts male patients at risk of post-COVID autoimmune exacerbation emphasizing the need for appropriate follow-up.

No association was found between AIRE loss of function variants and COVID-19 outcome, as outlined by the absence of the gene in Figure 1.

In conclusion, we have identified the second protein-encoding polymorphism that modulates COVID-19 outcome. These results indicate that L412F polymorphism in the TLR3 gene makes males, in whom after puberty testosterone lowers TLR3 expression, at risk of severe COVID-19 in a context of a polygenic model. Moreover, based on impairment of autophagy, these data provide a rationale for reinterpreting clinical trials with HCQ stratifying patients by L412F. Finally, the combination of L412F in TLR3 and specific HLA class II haplotypes may put male patients at risk of post-acute sequelae of SARS-CoV-2 infection (PASC) pointing to the need for an appropriate follow-up. Our experiments suggest an important role of autophagy downstream the TLR3 receptor, possibly affecting TNFa production and susceptibility to infections, including SARS-CoV-2.
MATERIAL AND METHODS

Patients

We performed a nested case-control study (NCC). We used a cohort of 1319 subjects (cases and controls) from the Italian GEN-COVID Multicenter study, infected with SARS-CoV-2 diagnosed by RT-PCR on nasopharyngeal swab [47]. Cases were defined as patients needing endotracheal intubation or CPAP/biPAP ventilation. Controls were oligo-asymptomatic subjects not requiring hospitalization.

LASSO logistic regression

We adopted the LASSO logistic regression model for the classification of severe COVID-19 patients (cases) versus SARS-CoV-2 PCR-positive oligo-asymptomatic subjects (controls), able to enforce both the sparsity and the interpretability of the results. By denoting with $\beta$ the coefficients of the logistic regression and by lambda ($\lambda$) the strength of the regularization, the LASSO (Least Absolute Shrinkage and Selection Operator) regularization term of the loss, has the effect of shrinking the estimated coefficients to 0. In this way, the weights of the logistic regression algorithm can be interpreted as the feature importances of the subset of the most relevant features for the task [49]. The input features are the common bi-allelic polymorphisms from whole-exome sequencing as well as gender, and the age, the latter as a continuous variable normalized between 0 and 1. Common bi-allelic polymorphisms are defined as combinations of two polymorphisms, each with MAF above 1%, with frequency above 5% in the cohort.

The fundamental hyper-parameter of the logistic regression algorithm is the strength of the LASSO term, which is tuned with a grid search method on the average area under the Receiver Operating Characteristic (ROC) curve for the 10-fold cross-validation. The regularization hyperparameter varies in the range $[10^{-3}, 10^{2}]$ with 50 equally spaced values in the logarithmic scale. The optimal regularization parameter is chosen by selecting the
parameter with the highest cross-validation score. During the fitting procedure, the class slight unbalancing is tackled by penalizing the misclassification of the minority class with a multiplicative factor inversely proportional to the class frequencies. The data pre-processing was coded in Python, whereas for the logistic regression model the scikit-learn module with the liblinear coordinate descent optimization algorithm was used. Performances of the model were evaluated using the cross-validation confusion matrix as well as by computing precision, sensitivity, specificity, and the Receiver Operating Characteristic (ROC) curve.

Cell culture and transfection

HEK-Dual™ Null (NF/IL8) cells (Invivogen) cells were cultured in Dulbecco modified Eagle medium (DMEM, Euroclone ECB7501L) supplemented with 10% fetal bovine serum (FBS; Euroclone, ECS0180L), 2 mM L-glutamine and 100 units/ml penicillin-streptomycin at 37°C in an atmosphere of 5% CO2:air. Transfections were performed with 1 μg DNA plasmid using lipofectamine LTX (Life Technologies, 15338500). The cells were seeded to be 70% to 80% confluent, then DNA was diluted in DMEM with 10 mM HEPES. Lipofectamine LTX was next added to the complex (5 μl) to allow creation of complexes (30 min at RT). Ultimately, DNA-lipid complexes were added to cells. Bafilomycin A1 (Santa Cruz Biotechnology, sc-201550). Human primary fibroblasts were obtained from the Genetic Biobank of Siena. Fibroblasts were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) (Biochrom GmbH, Berlin, Germany) supplemented with 10% Fetal Bovine Serum (FBS) (Carlo Erba), 2% L-glutamine (Carlo Erba) and 1% antibiotics (Penicillin/Streptomycin) (Carlo Erba), according to standard protocols, and routinely passed 1:2 with Trypsin/EDTA (0.05%) solution (Irvine Scientific Santa Ana, California, US).
**Immunofluorescence (IF)**

Cells were fixed with 4% paraformaldehyde in PBS for 20 min, washed with phosphate-buffered saline (PBS; Oxoid, BR0014G) and then permeabilized with digitonin solution (Life Technologies, BN2006) for 20 minutes. Then, the cells were washed three times in PBS. Permeabilized cells were incubated with anti-LC3B primary antibody (MBL, M152–3) for 1 h, washed three times with PBS, and then incubated with anti-mouse Alexa Fluor 488-conjugated secondary antibody (Life Technologies, A21202); subsequently cells were washed three times with PBS. Nuclei were stained with a solution of 6 μM of 4',6-diamidino-2-phenylindole (DAPI; Sigma Aldrich, D9542) in PBS for 10 min. Coverslips were mounted in fluorescence mounting medium (Dako, S3023). Samples were visualized on a TSC SP5 confocal microscope (Leica Microsystems, 5100000750) installed on an inverted LEICA DMI 6000CS (Leica Microsystems, 10741320) microscope and equipped with an oil immersion PlanApo 63× 1.4 NA objective. Images were acquired using the LAS AF acquisition software (Leica Microsystems, 10210).

**Dot count and statistical analysis for autophagy**

For the LC3B-positive dot count, we performed intensitometric analysis of fluorescence using the Quantitation Module of Volocity software (PerkinElmer Life Science). Dot count was subjected to statistical analysis. Measures were obtained by analyzing at least 400 cells/sample from 3 different experiments. Significance (P value) was assessed by Student’s t test, using GraphPad Prism6 software. Asterisks were attributed for the following significance values: P > 0.05 (ns), P < 0.05 (*), P < 0.01 (**), P < 0.001 (***).
Real time qPCR analysis of TNF-α expression

Total RNA was isolated using the RNAeasy Mini Kit (Quiagen, Hilden, Germany) according to the manufacturer’s instructions. cDNA synthesis was performed using the Maxima First Strand cDNA Synthesis Kit (Life Technologies, CA, USA). Neo synthetized cDNA was used to perform Real Time PCR using the PowerUp Sybr Green (Life Technologies, CA, USA). Following primers were used TNFα Fw CTATCTGGGAGGGGTCTTCC; TNFα Rw GGTTGAGGGTGCTCTGAAGGA; HPRT1 Fw GTCTTGCTCGAGATGTGATG and HPRT1 Rw GTAATCCAGCAGGTCAGCAA. Target transcripts were analyzed with the QuantStudio 7 System (Applied Biosystems, CA, USA). The comparative threshold cycle (Ct) method was used for quantification analysis. The Ct values of each gene were normalized to the Ct value of HPRT1. The gene expression levels were evaluated by the fold change using the equation $2^{-\Delta\Delta Ct}$.

HLA sequencing

HLA-class I and II genes were targeted for DNA sequencing using a biotinylated DNA probe-based capture method [PMID: 27486779], with modifications as follows. Genomic DNA (500ng from each sample) was fragmented enzymatically using the NEBNext Ultra ii FS module (New England Biolabs, Boston, MA). Individual samples were labeled uniquely using 3ul of 15uM custom dual-index adapters (Integrated DNA Technologies, Coralville, IA) and the NEB ligation module. Post ligation cleanup was based on the Kapa Hyper Prep protocol (Kapa Biosystems, Wilmington, MA) and followed by dual size selection. Paired ends of 250bp each were sequenced using a NovaSeq instrument and SP Reagent Kit (Illumina Inc, San Diego, CA). HLA alleles were determined from the sequence data using the consensus from
three algorithms: NGSengine 2.10.0 (GenDX, Utrecht, the Netherlands), HLA Twin (Omixon Biocomputing Ltd. Budapest, Hungary) and HLA*LA [PMID: 30942877].

ACKNOWLEDGEMENTS

This study is part of the GEN-COVID Multicenter Study, https://sites.google.com/dbm.unisi.it/gen-covid, the Italian multicenter study aimed at identifying the COVID-19 host genetic bases. Specimens were provided by the COVID-19 Biobank of Siena, which is part of the Genetic Biobank of Siena, member of BBMRI-IT, of Telethon Network of Genetic Biobanks (project no. GTB18001), of EuroBioBank, and of RD-Connect. We thank the CINECA consortium for providing computational resources and the Network for Italian Genomes (NIG) http://www.nig.cineca.it for its support. We thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). PJN was supported by a grant from fastgrants.org. We also thank the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/) and MIUR project “Dipartimenti di Eccellenza 2018-2020” to the Department of Medical Biotechnologies University of Siena, Italy. We thanks Dr. Margherita Leonardi for the experimental contribution in the autophagy data analysis. TDJF has received the Post-Doctoral fellowship from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) of Brazil.
ETHICS APPROVAL

The GEN-COVID study was approved by the University Hospital of Siena Ethical Review Board (Protocol n. 16929, dated March 16, 2020).

AUTHOR CONTRIBUTIONS

SC, CF and IM were in charge of biological samples’ collection and biobanking. CF and SD were in charge of DNA isolations from peripheral blood samples and carried out the sequencing experiments. MB, MP, FF and FMo and FMa were in charge of clinical data collection. EB, NP, and SF performed bioinformatics and statistical analyses. MLC, LDS, GB and DA prepared Figures and Tables. MB, FF, AR, FM, AMI, MUM, CB and AA performed analysis/interpretation of clinical data. MAV and FC were in charge of functional analysis for TLR3 L142F activity in HEK cells. MVC and OS performed structural biology analysis on protein models. FI performed autophagy experiments. SA provided TLR3 plasmids. SC, MUM, IM, AR, SM wrote and edited the manuscript. MUM, AR, IM, AMI, AA, MC, EF and FM designed the study. TDJf and PJN performed HLA sequencing. AA, SC and IM analysed HLA data. All authors have reviewed and approved the manuscript.

DISCLOSURE STATEMENT

The authors declare no competing interests.
REFERENCES

1. Lee IH, Lee JW, Kong SW. A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations. Infect Genet Evol. 2020 85:104507. doi: 10.1016/j.meegid.2020.104507.

2. Mukherjee S, Huda S, Sinha Babu SP. Toll-like receptor polymorphism in host immune response to infectious diseases: A review. Scand J Immunol. 2019 Jul;90(1):e12771. doi: 10.1111/sji.12771.

3. Perales-Linares R, Navas-Martin S. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology. 2013 Oct;140(2):153-67. doi: 10.1111/imm.12143.

4. Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, Baric RS. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. mBio. 2015 May 26;6(3):e00638-15. doi: 10.1128/mBio.00638-15.

5. Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3 pathway. Rev Med Virol. 2011 Mar;21(2):67-77. doi: 10.1002/rmv.680.

6. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005 Feb 24;433(7028):887-92. doi: 10.1038/nature03326.

7. Suresh MV, Dolgachev VA, Zhang B, Balijepalli S, Swamy S, Mooliyil J, Kralovich G, Thomas B, Machado-Aranda D, Karmakar M, Lalwani S, Subramanian A, Anantharam A, Moore BB, Raghavendran K. TLR3 absence confers increased survival with improved macrophage activity against pneumonia. JCI Insight. 2019 Dec 5;4(23):e131195. doi: 10.1172/jci.insight.131195.

8. C T Ranjith-Kumar, W Miller, J Sun, J Xiong, J Santos, I Yarbrough et al. Effects of
single nucleotide polymorphisms on Toll-like receptor 3 activity and expression in cultured cells. *J Biol Chem.* 2007 Jun 15;282(24):17696-705. doi: 10.1074/jbc.M700209200.

9. Teimouri H, Maali A. Single-Nucleotide Polymorphisms in Host Pattern-Recognition Receptors Show Association with Antiviral Responses against SARS-CoV-2, in-silico Trial. *JoMMID.* 2020; 8 (2) :65-70.

10. Dhangadamajhi G, Rout R. Association of TLR3 functional variant (rs3775291) with COVID-19 susceptibility and death: a population-scale study. *Hum Cell.* 2021 Feb 22;1–3. doi: 10.1007/s13577-021-00510-6.

11. Franco LH, Fleuri AKA, Pellison NC, Quirino GFS, Horta CV, de Carvalho RVH, Oliveira SC, Zamboni DS. Autophagy downstream of endosomal Toll-like receptor signaling in macrophages is a key mechanism for resistance to Leishmania major infection. *J Biol Chem.* 2017 Aug 11;292(32):13087-13096. doi: 10.1074/jbc.M117.780981.

12. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. *EMBO J.* 2008 Apr 9;27(7):1110-21. doi: 10.1038/emboj.2008.31.

13. Kirkin V, McEwan DG, Novak I, Dikic I. A role for ubiquitin in selective autophagy. *Mol Cell.* 2009 May 15;34(3):259-69. doi: 10.1016/j.molcel.2009.04.026.

14. Johansen JP, Christopher K. Cain, Linnaea E. Ostroff, Joseph E. LeDoux, Molecular Mechanisms of Fear Learning and Memory. *Cell.* 2011, 147(3):509-524, doi: 10.1016/j.cell.2011.10.009.

15. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. *Nature.* 2011 Jan 20;469(7330):323-35. doi: 10.1038/nature09782

16. Prentice E, Jerome WG, Yoshimori T, Mizushima N, Denison MR. Coronavirus replication complex formation utilizes components of cellular autophagy. *J Biol Chem.*
2004 Mar 12;279(11):10136-41. doi: 10.1074/jbc.M306124200.

17. Guo L, Yu H, Gu W, Luo X, Li R, Zhang J, Xu Y, Yang L, Shen N, Feng L, Wang Y. Autophagy Negatively Regulates Transmissible Gastroenteritis Virus Replication. Sci Rep. 2016 Mar 31;6:23864. doi: 10.1038/srep23864.

18. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, Flament T, Ferreira-Maldent N, Bruyère F, Stefic K, Gaudy-Graffin C, Grammatico-Guillon L, Bernard L. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021 Feb;27(2):258-263. doi: 10.1016/j.cmi.2020.09.052.

19. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.

20. Miao Y, Fan L, Li JY. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. Front Immunol. 2020 Jun 16;11:1445. doi: 10.3389/fimmu.2020.01445.

21. Shojaei S, Suresh M, Klionsky DJ, Labouta HI, Ghavami S. Autophagy and SARS-CoV-2 infection: A possible smart targeting of the autophagy pathway. Virulence. 2020 Dec;11(1):805-810. doi: 10.1080/21505594.2020.1780088.

22. Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, Ciccozzi M, Cassone A. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. J Infect. 2020 Jul;81(1):e24-e27. doi: 10.1016/j.jinf.2020.03.058

23. Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight
into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. *Life Sci.* 2020 Sep 15;257:118105. doi: 10.1016/j.lfs.2020.118105.

24. Torcia MG, Nencioni L, Clemente AM, Civitelli L, Celestino I, Limongi D, Fadigati G, Perissi E, Cozzolino F, Garaci E, Palamara AT. Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males. *PLoS One.* 2012;7(6):e39853. doi: 10.1371/journal.pone.0039853.

25. Lim HK, Huang SXL, Chen J, Kerner G, Gilliaux O, Bastard P, Dobbs K, Hernandez N, Goudin N, Hasek ML, García Reino EJ, Lafaille FG, Lorenzo L, Luthra P, Kochetkov T, Bigio B, Boucherit S, Rozenberg F, Vedrinne C, Keller MD, Itan Y, García-Sastre A, Celard M, Orange JS, Ciancanelli MJ, Meyts I, Zhang Q, Abel L, Notarangelo LD, Snoeck HW, Casanova JL, Zhang SY. Severe influenza pneumonitis in children with inherited TLR3 deficiency. *J Exp Med.* 2019 Sep 2;216(9):2038-2056. doi: 10.1084/jem.20181621.

26. Q Zhang, P Bastard, Z Liu, J Le Pen, M Moncada-Velez, J Chen et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020 Oct 23;370(6515):eabd4570. doi: 10.1126/science.abd4570.

27. Enkhbayar P, Kamiya M, Osaki M, Matsumoto T, Matsushima N. Structural principles of leucine-rich repeat (LRR) proteins. *Proteins.* 2004 Feb 15;54(3):394-403. doi: 10.1002/prot.10605.

28. Rothberg JM, Jacobs JR, Goodman CS, Artavanis-Tsakonas S. slit: an extracellular protein necessary for development of midline glia and commissural axon pathways contains both EGF and LRR domains. *Genes Dev.* 1990 Dec;4(12A):2169-87. doi: 10.1101/gad.4.12a.2169.

29. Kobe B, Kajava AV. The leucine-rich repeat as a protein recognition motif. *Curr Opin*
30. Gao T, Zhang SP, Wang JF, Liu L, Wang Y, Cao ZY, Hu QK, Yuan WJ, Lin L. TLR3 contributes to persistent autophagy and heart failure in mice after myocardial infarction. *J Cell Mol Med.* 2018 Jan;22(1):395-408. doi: 10.1111/jcmm.13328.

31. Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet.* 2020 Jun 13;395(10240):1820. doi: 10.1016/S0140-6736(20)31324-6.

32. Mahase E. Covid-19: WHO halts hydroxychloroquine trial to review links with increased mortality risk. *BMJ.* 2020 May 28;369:m2126. doi: 10.1136/bmj.m2126.

33. Ayele Mega T, Feyissa TM, Dessalegn Bosho D, Kumela Goro K, Zeleke Negera G. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. *Can Respir J.* 2020 Oct 13;2020:4312519. doi: 10.1155/2020/4312519.

34. Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, *et al*. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy.* 2021 Feb 8:1-382. doi: 10.1080/15548627.2020.1797280.

35. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. *Nat Rev Cancer.* 2017 Sep;17(9):528-542. doi: 10.1038/nrc.2017.53. Epub 2017 Jul 28. PMID: 28751651; PMCID: PMC5975367.

36. Michalakis K, Ilias I. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. *Diabetes Metab Syndr.* 2020 Jul-Aug;14(4):469-471. doi: 10.1016/j.dsx.2020.04.033.

37. Vomero M, Barbati C, Colasanti T, Celia AI, Speziali M, Ucci FM, Ciancarella C, Conti F, Alessandri C. Autophagy Modulation in Lymphocytes From COVID-19 Patients:
New Therapeutic Target in SARS-COV-2 Infection. *Front Pharmacol.* 2020 Nov 19;11:569849. doi: 10.3389/fphar.2020.569849

38. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. *Rheumatology* (Oxford). 2006 Jun;45(6):703-10. doi: 10.1093/rheumatology/kei282.

39. Nahum A, H Dadiac, A Batesac, C M Roifman et al. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. *Autoimmun Rev* 2012 Mar;11(5):341-7. doi: 10.1016/j.autrev.2011.10.007.

40. Aslaksen S, Wolff AB, Vigeland MD, Breivik L, Sheng Y, Oftedal BE, Artaza H, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E. Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease. *J Transl Autoimmun.* 2019 May 28;1:100005. doi: 10.1016/j.jtauto.2019.100005.

41. Wu DJ, Adamopoulos IE. Autophagy and autoimmunity. *Clin Immunol.* 2017 Mar;176:55-62. doi: 10.1016/j.clim.2017.01.007.

42. Caza TN, Talaber G, Perl A. Metabolic regulation of organelle homeostasis in lupus T cells. *Clin Immunol.* 2012 Sep;144(3):200-13. doi: 10.1016/j.clim.2012.07.001.

43. Keller CW, Lünemann JD. Autophagy and Autophagy-Related Proteins in CNS Autoimmunity. *Front Immunol.* 2017 Feb 27;8:165. doi: 10.3389/fimmu.2017.00165.

44. de Sousa E, Ligeiro D, Lérias JR, Zhang C, Agrati C, Osman M, El-Kafrawy SA, Azhar EI, Ippolito G, Wang FS, Zunla A, Maeruer M. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants. *Int J Infect Dis.* 2020
45. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, Fougner KJ, Berg TJ, Bollerslev J, Mella B, Carlson JA, Erlich H, Husebye ES. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. *J Clin Endocrinol Metab*. 2009 Dec;94(12):4882-90. doi: 10.1210/jc.2009-1368.

46. Smigoc Schweiger D, Mendez A, Kunilo Jamnik S, Bratanic N, Bratina N, Battelino T, Brecelj J, Vidan-Jeras B. High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease. *Autoimmunity*. 2016 Jun;49(4):240-7. doi: 10.3109/08916934.2016.1164144.

47. Daga S, Fallerini C, Baldassarri M, Fava F, Valentino F, Doddato G, Benetti E, Furini S, Giliberti A, Tita R, Amitrano S, Bruttini M, Meloni I, Pinto AM, Raimondi F, Stella A, Biscarini F, Picchiotti N, Gori M, Pinoli P, Ceri S, Sanarico M, Crawley FP, Birolo G; GEN-COVID Multicenter Study, Renieri A, Mari F, Frullanti E. Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. *Eur J Hum Genet*. 2021 Jan; 17:1–15. doi: 10.1038/s41431-020-00793-7.

48. Molnar, R. Interpretable machine learning. A Guide for Making Black Box Models Explainable. 2020.

49. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society. Series B (Methodological)*. 1996; 58(1), 267-288.
GEN-COVID Multicenter Study (https://sites.google.com/dbm.unisi.it/gen-covid)

Mirella Bruttini1,2,3, Rossella Tita3, Sara Amitrano3, Anna Maria Pinto3, Maria Antonietta Mencarelli3, Caterina Lo Rizzo3, Valentina Perticaroli1,2,3, Massimiliano Fabbiani3, Barbara Rossetti3, Giacomo Zanelli2,9, Elena Bargagli10, Laura Bergantini10, Miriana D’Alessandro10, Paolo Cameli10, David Bennett10, Federico Anedda11, Simona Marcantoni11, Sabino Scoletta11, Federico Franchi11, Maria Antonietta Mazzei12, Susanna Guerrini12, Edoardo Conticini13, Luca Cantarini13, Bruno Frediani13, Danilo Tacconi14, Chiara Spertilli14, Marco Feri15, Alice Donati15, Raffaele Scala16, Luca Guidelli16, Genni Spargi17, Marta Corridi17, Cesira Nencioni18, Leonardo Croci18, Gian Piero Caldarelli19, Maurizio Spagnesi20, Paolo Piacentini20, Maria Bandin20, Elena Desanctis20, Silvia Cappelli20, Anna Canaccini21, Agnese Verzuri21, Valentina Anemoli21, Agostino Ognibene22, Alessandro Pancrazi22, Maria Lorubbio22, Massimo Vaghi23, Antonella D’Arminio Monforte24, Esther Merlini24, Federica Gaia Miraglia24, Raffaele Bruno25,26, Marco Vecchia25, Serena Ludovisi25,26, Massimo Girardi27, Sophie Venturelli27, Marco Sita27, Andrea Cossarizza28, Andrea Antinori29, Alessandra Vergori29, Arianna Emiliozzi29, Stefano Rusconi30,31, Matteo Siano31, Arianna Gabrieli31, Agostino Riva30,31, Daniela Francisci32,33, Elisabetta Schiaroli32, Francesco Paciosi32, Pier Giorgio Scotton34, Francesca Andretta34, Sandro Panese35, Renzo Scaggiante36, Francesca Gatti36, Saverio Giuseppe Parisi37, Melania degli Antoni38, Isabella Zanella39,40, Matteo Della Monica41, Carmelo Piscopo41, Mario Capasso42,43,44, Roberta Russo42,43, Immacolata Andolfi42,43, Achille Iolascon42,43, Giuseppe Fiorentino45, Massimo Carella46, Marco Castori46, Filippo Auccella47, Pamela Raggi48, Carmen Marciano48, Rita Perna48, Matteo Bassetti49,50, Antonio Di Biagio50, Maurizio Sanguinetti51,52, Luca Masucci51,52, Serafina Valente53, Marco Mandalà54, Alessia Giori54, Lorenzo Salerni54, Patrizia Zucchi55, Pierpaolo Parravicini55, Elisabetta Menatti56, Stefano Baratti57, Tullio Troatta58, Ferdinando Giannattasio58, Gabriella Coiro58, Fabio Lena59, Domenico A. Coviello60, Cristina Mussini61, Giancarlo Bosio62, Enrico Martinelli62, Sandro Mancarella63, Luisa Tavecchia63, Mary Ann Belli63, Lia Crotti64,65,66,67, Gianfranco Parati64,65, Marco Gori68,69, Maurizio Sanarico70, Stefano Ceri71, Pietro Pinoli71, Francesco Raimondi72, Filippo Biscarini73, Alessandra Stella73, Marco Rizzi74, Franco Maggiolo74, Diego Ripamonti74, Claudia Suardi75, Tiziana Bachetti76, Maria Teresa La Rovere77,
Simona Sarzi-Braga, Maurizio Bussotti, Mattia Bergomi, Katia Capitani, Kristina Zguro, Simona Dei, Sabrina Ravaglia, Rosangela Artuso, Antonio Perrella, Francesco Bianchi, Giuseppe Merla, Gabriella Maria Squeo.
34. Department of Infectious Diseases, Treviso Hospital, Local Health Unit 2 Marca Trevigiana, Treviso, Italy
35. Clinical Infectious Diseases, Mestre Hospital, Venezia, Italy.
36. Infectious Diseases Clinic, ULSS1, Belluno, Italy
37. Department of Molecular Medicine, University of Padova, Italy
38. Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
39. Department of Molecular and Translational Medicine, University of Brescia, Italy;
40. Clinical Chemistry Laboratory, Cytogenetics and Molecular Genetics Section, Diagnostic Department, ASST Spedali Civili di Brescia, Italy
41. Medical Genetics and Laboratory of Medical Genetics Unit, A.O.R.N. "Antonio Cardarelli", Naples, Italy
42. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
43. CEINGE Biotecnologie Avanzate, Naples, Italy
44. IRCCS SDN, Naples, Italy
45. Unit of Respiratory Physiopathology, AORN dei Colli, Monaldi Hospital, Naples, Italy
46. Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
47. Department of Medical Sciences, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
48. Clinical Trial Office, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
49. Department of Health Sciences, University of Genova, Genova, Italy
50. Infectious Diseases Clinic, Policlinico San Martino Hospital, IRCCS for Cancer Research Genova, Italy
51. Microbiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Medicine, Rome, Italy
52. Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
53. Department of Cardiovascular Diseases, University of Siena, Siena, Italy
54. Otolaryngology Unit, University of Siena, Italy
55. Department of Internal Medicine, ASST Valtellina e Alto Lario, Sondrio, Italy
56. Study Coordinator Oncologia Medica e Ufficio Flussi, Sondrio, Italy
57. Department of Infectious and Tropical Diseases, University of Padova, Padova, Italy
58. First Aid Department, Luigi Curto Hospital, Polla, Salerno, Italy
59. Local Health Unit-Pharmaceutical Department of Grosseto, Toscana Sud Est Local Health Unit, Grosseto, Italy
60. U.O.C. Laboratorio di Genetica Umana, IRCCS Istituto G. Gaslini, Genova, Italy.
61. Infectious Diseases Clinics, University of Modena and Reggio Emilia, Modena, Italy.
62. Department of Respiratory Diseases, Azienda Ospedaliera di Cremona, Cremona, Italy
63. U.O.C. Medicina, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo (MI), Italy
64. Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.
65. Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
66. Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy.
67. Istituto Auxologico Italiano, IRCCS, Laboratory of Cardiovascular Genetics, Milan, Italy.
68. University of Siena, DIISM-SAILAB, Siena, Italy
69. University Cote d'Azur, Inria, CNRS, I3S, Maasai
70. Independent Data Scientist, Milan, Italy
71. Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milano, Italy
72. Scuola Normale Superiore, Pisa, Italy
73. CNR-Consiglio Nazionale delle Ricerche, Istituto di Biologia e Biotecnologia Agraria (IBBA), Milano, Italy.
74. Unit of Infectious Diseases, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
75. Fondazione per la ricerca Ospedale di Bergamo, Bergamo, Italy
76. Direzione Scientifica, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
77. Istituti Clinici Scientifici Maugeri IRCCS, Department of Cardiology, Institute of Montescano, Pavia, Italy.
78. Istituti Clinici Scientifici Maugeri IRCCS, Department of Cardiac Rehabilitation, Institute of Tradate (VA), Italy.
79. Cardiac Rehabilitation Unit, Fondazione Salvatore Maugeri, IRCCS, Scientific Institute of Milan, Milan, Italy.
80. Veos Digital, Milan, Italy
81. Core Research Laboratory, ISPRO, Florence, Italy
82. Health Management, Azienda USL Toscana Sudest, Tuscany, Italy
83. IRCCS C. Mondino Foundation, Pavia, Italy
84. Medical Genetics Unit, Meyer Children's University Hospital, Florence, Italy
85. Department of Medicine, Pneumology Unit, Misericordia Hospital, Grosseto, Italy.
86. Laboratory of Regulatory and Functional Genomics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy
FIGURES LEGEND

**Fig.1** The histogram of the LASSO logistic regression weights represents the importance of each feature for the classification task, **Panel A**. The positive weights reflect a susceptible behaviour of the features to the target COVID-19 disease, whereas the negative weights a protective action. **Panel B**: Cross-validation ROC-AUC score for the grid of LASSO regularization parameters; the error bar is given by the standard deviation of the score within the 10 folds; the optimal regularization parameter is chosen by selecting the one with highest cross-validation score (red point). **Panel C**: Boxplot of accuracy, precision, sensitivity, specificity, and ROC-AUC score for the 10-fold of the cross-validation. The box extends from the Q1 to Q3 quartile, with a line at the median (Q2) and a triangle for the average. **Panel D**: Confusion matrix for the aggregation of the logistic regression predictions in the 10 folds of the cross-validation. **Panel E**: ROC curve for the 10 folds of the cross-validation. **Panel F**: Distribution of carriers of the polymorphism L412F in homozygous or heterozygous states stratified by clinical category.

**Figure 2** Superposition of wild type and mutated TLR3 protein. **Panel A**: TRL3 human protein tridimensional structure of 2Z7X crystal structure. In green cartoon representation of TLR3 protein. In **Panel B** and **Panel C** zoom of mutated region with LEU412 in red sticks and PHE412 in magenta. The hydrophobic core of Leu377, Leu389, and Trp386 in blue sticks.

**Fig. 3. Analysis of autophagy in TLR3_L412F expressing cells. Panel A**: 28-day survival study of TLR3- L412F carriers vs not-carriers in the group treated with hydroxychloroquine. N=156, with 73 carriers of TLR3- L412F. 3 carriers and 1 not-carrier died in the first 28 days of treatment. **Panel B**: Analysis of autophagy in HEK-KO cells expressing wild type or L412F mutant proteins. HEK-KO cells were transfected for 24 hrs with plasmids encoding TLR3_WT and TLR3_L412F. Cells were next incubated in full medium (FM) or FM + 400 nM Bafalomycin A1 (BAF A1) for 3 hrs and stimulated for increasing times with 50 μg/ml Poly(I:C), as indicated. Cells were next fixed, permeabilized with 100 μg/ml digitonin and stained with anti-LC3B antibodies and revealed with AlexaFluor488-conjugated secondary antibodies. Nuclei were stained with DAPI. Where indicated, rapamycin (RAP, 500 nM, for 2 hrs) was used as positive control for induction of autophagy. **Panel C**: Same as in B, but the amount of autophagosomes (scored as LC3B-positive dots) per cell was quantified by Volocity.
software. Measures were obtained by analyzing at least 400 cells/sample from 3 different experiments (n = 3). **Panel D:** Analysis of TNF-α mRNA expression in HEK-KO cells expressing wild type or L412F mutant proteins. HEK-KO cells were transfected for 24 hrs with plasmids encoding empty vector (CTR), TLR3_WT and TLR3_L412F and next stimulated for increasing times with 50 µg/ml Poly(I:C), where indicated. TNF-α levels were evaluated by Real Time PCR. The gene expression levels were evaluated by the fold change versus TLR2 WT sample using the equation $2^{-\Delta\Delta C_t}$. Data are presented as the mean ± SEM. Data significance was analyzed using One-way ANOVA test with Holm-Sidak’s correction. Asterisks were attributed for the following significance values: P > 0.05 (ns), P < 0.05 (*) and P < 0.01 (**).

**Panel E:** Normal human fibroblasts (NDHF) from subjects expressing the TLR3_WT receptor were stimulated with 50 µg/ml Poly(I:C) or RAP (1 µ M) for 4 hrs, in full medium alone or containing 400 nM bafilomycin A1 for 3 h. Cells were next fixed, permeabilized with 100 µg/ml digitonin and stained with anti-LC3B antibodies and revealed with AlexaFluor488-conjugated secondary antibodies. Nuclei were stained with DAPI. **Panel F:** Same as in E, but the number of autophagosomes (scored as LC3B-positive dots) per cell was evaluated for each sample by Volocity software. G and H) same as in E-F, but fibroblasts are homozygous for the TLR3_L412F receptor. Statistical analysis was performed using Student’s t test. Means § SEM for each value are shown in the graphs. ns=not significant; ** = p < 0.01; *** = p < 0.001.
### Table 1a. L412F and COVID-19 outcome (both sexes)

|                | Cases          | Controls       | Marginal Row Totals |
|----------------|----------------|----------------|---------------------|
| **L412F**      | 186 (55.0%)    | 139 (46.3%)    | 325 (50.9%)         |
| **Wild-Type**  | 152 (45.0%)    | 161 (53.7%)    | 313 (49.05%)        |
| **Marginal Column Totals** | 338 (52.97%) | 300 (47.02%) | 638 (Grand Total) |

p-value (cases vs controls) = 2.8x10^{-2}

### Table 1b. L412F and COVID-19 outcome (males only)

|                | Cases          | Controls       | Marginal Row Totals |
|----------------|----------------|----------------|---------------------|
| **L412F**      | 131 (55.3%)    | 45 (38.8%)     | 176 (49.8%)         |
| **Wild-Type**  | 106 (44.7%)    | 71 (61.2%)     | 177 (50.1%)         |
| **Marginal Column Totals** | 237 (67.13%) | 116 (32.86%) | 353 (Grand Total) |

p-value (cases vs controls) = 3.6x10^{-3}

### Table 1c. L412F and COVID-19 outcome (females only)

|                | Cases          | Controls       | Marginal Row Totals |
|----------------|----------------|----------------|---------------------|
| **L412F**      | 55 (54.5%)     | 94 (51.1%)     | 149 (5.3%)          |
| **Wild-Type**  | 46 (45.5%)     | 90 (48.9%)     | 136 (47.7%)         |
| **Marginal Column Totals** | 101 (35.43%) | 184 (64.56%) | 285 (Grand Total) |

p-value (cases vs controls) = 5.8x10^{1}
Table 2a. Association between DR3-DQ2 + L412F haplotype and autoimmune disorders in male patients

| DR3-DQ2 + L412F | With autoimmune disease | W/O autoimmune disease | Marginal Row |
|------------------|-------------------------|------------------------|--------------|
|                  |                         |                        | Totals       |
| 12 (3.59%)       | 12 (3.59%)              | 24 (7.18%)             | 34 (Grand Total) |
| Other            | 64 (19.16%)             | 246 (73.65%)           | 310 (92.81%) |
| Marginal Column Totals | 76 (22.75%)           | 258 (77.24%)           | 334 (Grand Total) |

p-value (cases vs controls) = 0.000951

Table 2b. Male patients with L412F and HLA DR3/DQ2 haplotype

| PatientID       | Age | Ethnicity (white=1, hispanic=4) | Clinical Category                  | GT TLR3 (L412F) | Clinical known comorbidities                                      |
|-----------------|-----|---------------------------------|------------------------------------|-----------------|------------------------------------------------------------------|
| AR-COV-25       | 69  | 1                               | 4                                 | 0/1             | Hypertension, Kidney failure, COLD                                 |
| BS-COV-102      | 59  | 1                               | 3                                 | 0/1             | Diabetes Mellitus, diabetic neuropathy with transmetatarsal amputation, bilateral fachiectomy, left hernioplasty, diabetic retinopathy |
| BS-COV-58       | 47  | 1                               | 3                                 | 0/1             | Hypertension                                                      |
| BS-COV-65       | 72  | 1                               | 2                                 | 0/1             | Rheumatoid Arthritis                                              |
| BS-COV-70       | 65  | 1                               | 3                                 | 0/1             | Autoimmune hepatitis, autoimmune polygliandol syndrome, previous autoimmune thyroid |
| CR-COV-17       | 61  | 1                               | 2                                 | 0/1             | Inflammatory disease, Hypertension                                |
| CR-COV-4        | 66  | 1                               | 3                                 | 0/1             | None                                                             |
| LS-COV-10       | 37  | 1                               | 1                                 | 0/1             | DLB-CL EBV+, Immune deficiency, Bipolar Disorder                  |
| LS-COV-19       | 58  | 4                               | 2                                 | 0/1             | Diabetes Mellitus                                                |
| LS-COV-8        | 48  | 1                               | 4                                 | 0/1             | Hypertension                                                     |
| MORE-COV-16     | 65  | 1                               | 3                                 | 0/1             | Hypertension, Asthma, Dyslipidemia                               |
| MORE-COV-7      | 72  | 1                               | 4                                 | 0/1             | Hypertension                                                     |
| PG-COV-15       | 87  | 1                               | 2                                 | 0/1             | Congestive Heart failure, Dyslipidemia, N/A                      |
| PG-COV-23       | 68  | 1                               | 1                                 | 0/1             | N/A                                                              |
| PV-COV-02       | 65  | 1                               | 2                                 | 0/1             | Rheumatoid Arthritis                                              |
| PV-COV-23       | 72  | 1                               | 3                                 | 0/1             | Hypertension, Diabetes Mellitus                                  |
| PV-COV-24       | 79  | 1                               | 2                                 | 0/1             | Atrial Fibrillation, Diabetes Mellitus, Kidney failure            |
| PV-COV-39       | 33  | 4                               | 4                                 | 0/1             | Diabetes Mellitus, Obesity                                       |
| PV-COV-73       | 54  | 1                               | 3                                 | 0/1             | None                                                             |
| PV-COV-97       | 66  | 1                               | 4                                 | 0/1             | Congestive Heart Failure, Hypertension, Diabetes Mellitus         |
| RUF-COV-1       | 52  | 1                               | 0                                 | 0/1             | None                                                             |
| SPC-COV-14      | 56  | 1                               | 3                                 | 0/1             | Asthma, HCV                                                      |
| TV-COV-81       | 44  | 1                               | 1                                 | 0/1             | None                                                             |
| TV-COV-96       | 51  | 1                               | 2                                 | 0/1             | Hypertension                                                     |